Jim Wilson (WuXi Global Forum at JPM20)
November 12, 2020 09:26 AM ESTUpdated 11:59 AM
R&D
Cell/Gene Tx

Jim Wil­son of­fers a safer so­lu­tion to some of the in­dus­try's gene ther­a­py woes

Jason Mast

Editor

Jim Wil­son has been warn­ing for a while about the dan­gers of the vi­ral vec­tors used in most gene ther­a­pies. Two years ago he …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

Sarep­ta los­es CMO to RNA edit­ing up­start; An­oth­er wave of per­son­nel moves at Dyne

Sanofi to pay $125M up­front for two im­munol­o­gy drugs from lit­tle-known biotech

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

Biotech seed rounds sink to low­est lev­el in years as in­dus­try slump drags on

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times